Dental Care Europe supports BDN. Please visit our sponsor.

Web BiOpticDrivingNetwork.org

 

 

 BiOptic Driving Webboard Archive 11/02 to 12/03

Search this webboard  |  Next  |  Previous  |  Up

Archive 2/97 to 2/02  |  Archive 2/02 to 11/02 lost  |  Archive 12/03 to 3/04

To post a new message, please click here.

Re: anything new about stargardts

From: Robert B. Greer
Email: rbgreer@uclink.berkeley.edu
URL: spectacle.berkeley.edu
Date: July 21, 2003
Time: 18:33:09

Comments

I’m unaware of any discoveries that will reverse the effects of Stargardt disease or have been shown to slow or stop progression of the disease in humans. On the other hand, there have been some interesting findings reported in the literature recently about studies in animal models. In the April 15, 2003, issue of the Proceedings of the National Academy of Sciences of the United States of America (http://www.pnas.org/) there is an article titled: “Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt’s macular degeneration.” Isotretinoin, also known as Accutane, was found to inhibit the accumulation of lipofuscin in mice and, thus, retain retinal function. This is encouraging but does not address the issue of reversal, nor does it directly apply to humans. Human trials with Accutane may happen some day but care must be taken because Accutane is known to cause birth defects and its long-term side effects are not well understood.

Also in the Proceedings of the National Academy of Sciences of the United States of America, June 20, 2000, was an article published titled “Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration” that found lipofuscin accumulation was inhibited in mice with Stargardt disease reared in the dark. While no human trials have been conducted to see if similar results would occur, the study did go so far as to say “The observed inhibition of A2E accumulation in abcr-/- mice raised under total darkness suggests that limiting light exposure may reduce the rate of disease progression in humans with recessive ABCR-mediated diseases.” Once again, there is no direct evidence in humans that limiting light will slow or stop the progression of Stargardt disease nor does the evidence suggest that the disease can be reversed.

 
Last changed: August 15, 2010

 

 

 

 supported by Namehog,   Dental Care Europe,   and Dental Care London

 

All 2000+ pages on this website are BOBBY level 1 compliant, ensuring accessibility to all. We are working to achieve greeter accessibility and would be grateful for expert assistance. Please contact the Webmaster via the Webboard Community, link above. Contact Webmasters Accessibility   This page last edited: 15 August 2010
Back to the top

Hit Counter

hits since April 21 2002

© 2001-2010 BiOptic Drive Ltd.  All rights reserved.

Registered not for profit organisation in England and Wales, Company Type: PRI/LBG/NSC/S.30 Company No. 6361933

 

Disclaimer statement: BiOptic Drive Ltd does not sell, endorse, or offer opinions on products, manufacturers, or professionals whose services/products may be secured following posting on this website.  Products and individuals pictures on this site have been specifically authorized by the relevant manufacturer or individual.  We are a registered not for profit organization, and provide information to help make informed choices.  We do not give individuals optometric or ophthalmologic advice, but may refer one to an eminent expert.  A BiOptic Telescopic System does not itself make someone a safe driver; specialized training is prerequisite.